• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Expansion

SHS buys minority stake in Develco Pharma

  • Harriet Matthews
  • Harriet Matthews
  • 17 December 2020
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

SHS has acquired a minority stake in Germany-based drug developer Develco Pharma.

The investment is intended to accelerate the company's development of new drugs, according to a statement. New products are likely to focus on new indications and therapeutic areas.

The deal came about via a proprietary connection, with an introduction taking place at the start of 2020, Manfred Ulmer-Weber, partner at SHS, told Unquote: "We were able to meet before the lockdown started and saw that it could be an interesting situation for both parties. Develco is well established and has a strong growth pipeline, and as a specialised healthcare investor, we were able to bring not just money but also value to the table."

Ulmer-Weber is to join Develco's board of directors following the transaction, according to a statement.

SHS is investing via its fifth fund, which held a final close in July 2019 on €130m and has now made nine investments. The vehicle generally deploys equity tickets of up to €30m, with the option to provide up to €60m alongside co-investors. The fund focuses on healthcare, medical technology and diagnostics businesses.

The fund aims to make 12-15 deals in total, Ulmer-Weber said, and he expects the vehicle will make around five more deals in 2021 and 2022: "We are looking for growth cases and buyouts; we still have some dry powder in our fund."

Company
Develco provides development, approval and production of innovative and generic pharmaceutical products. The company also has a modular system of formulation technologies to manufacture orally administered drugs. Develco's client base comprises pharmaceutical companies that sell products on a global scale.

Develco was founded in 2006 and employs 120 staff. It is headquartered in Schopfheim, Germany, and also has operations in Switzerland.

People
SHS
– Hubertus Leonhardt (partner, managing director); Manfred Ulmer-Weber (partner).
Develco Pharma
– Mathias Scheer (chairman of the board of directors); Martin Renner (CEO).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • DACH
  • Healthcare
  • Germany

More on Expansion

Blackstone takes minority stake in Groupe Premium
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
e-Attestations aims to triple size with new Keensight backing
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
The Bolt-Ons Digest - 3 July 2023
The Bolt-Ons Digest - 3 July 2023

Unquoteт€™s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
The Bolt-Ons Digest - 26 May 2023
The Bolt-Ons Digest - 26 May 2023

Unquoteт€™s selection of the latest add-ons with H&F's TeamSystem, Nordic Capital's Regnology, 3'i's Dutch Bakery and more

  • Expansion
  • 26 May 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013